James F. Oliviero III
2019
In 2019, James F. Oliviero III earned a total compensation of $2.3M as President, Chief Executive Officer and Director at Checkpoint Therapeutics, a 8% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $252,000 |
|---|---|
| Salary | $480,000 |
| Stock Awards | $1,576,250 |
| Total | $2,308,250 |
Oliviero received $1.6M in stock awards, accounting for 68% of the total pay in 2019.
Oliviero also received $252K in non-equity incentive plan and $480K in salary.
Rankings
In 2019, James F. Oliviero III's compensation ranked 5,222nd out of 13,971 executives tracked by ExecPay. In other words, Oliviero earned more than 62.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,222 out of 13,971 | 63rd |
Division Manufacturing | 1,942 out of 5,701 | 66th |
Major group Chemicals And Allied Products | 683 out of 2,200 | 69th |
Industry group Drugs | 574 out of 1,886 | 70th |
Industry Pharmaceutical Preparations | 428 out of 1,398 | 69th |
Source: SEC filing on April 24, 2020.
Oliviero's colleagues
We found one more compensation record of an executive who worked with James F. Oliviero III at Checkpoint Therapeutics in 2019.
2019
William Gray
Checkpoint Therapeutics
Vice President, Finance and Accounting
News
Checkpoint Therapeutics CEO James Oliviero's 2023 pay slips 20% to $1.6M
April 2, 2024
Checkpoint Therapeutics CEO James Oliviero's 2022 pay slips 11% to $2M
May 1, 2023
Checkpoint Therapeutics CEO James Oliviero's 2021 pay stays at $2.3M
April 29, 2022
Checkpoint Therapeutics CEO James Oliviero's 2020 pay slips 1% to $2.3M
April 30, 2021
Checkpoint Therapeutics CEO James Oliviero's 2019 pay rises 8% to $2.3M
April 24, 2020
Checkpoint Therapeutics CEO James Oliviero's 2018 pay jumps 230% to $2.1M
April 30, 2019